UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2013
Commission File Number: 001-34563
CONCORD MEDICAL SERVICES HOLDINGS LIMITED
18/F, Tower A, Global Trade Center
36 North Third Ring Road East, Dongcheng District
Beijing 100013
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A
TABLE OF CONTENTS
TABLE OF CONTENTS
Exhibit 99.1 – Press release: Concord Medical Reports Second Quarter 2013 Financial Results
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CONCORD MEDICAL SERVICES HOLDINGS LIMITED | ||||
| By: | /s/ Jianyu Yang | |||
| Name: | Jianyu Yang | |||
| Title: | Chairman and Chief Executive Officer | |||
Date: August 13, 2013
Exhibit 99.1
Concord Medical Reports Second Quarter 2013 Financial Results
--2Q13 Total Net Revenue Increases 86% to RMB254 Million—
--2Q13 Adjusted EBITDA Growth of 11%--
--Reiterates Full Year Financial Forecast of 40%-47% Revenue Growth—
--Establishes Full Year Adjusted EBITDA Growth in Mid-teen Levels--
BEIJING, August 12, 2013 -- Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang’an Hospital, today reported its unaudited consolidated financial results for the second quarter ended June 30, 2013[1].
Second Quarter 2013 Highlights
| • | Total net revenue, which consists of net revenues generated from the network business and hospital business, was RMB254.0 million ($41.4 million) in the second quarter of 2013, an 86.1% increase from RMB136.5 million in the second quarter of 2012. |
| • | Gross profit in the second quarter of 2013 was RMB105.2 million ($17.1 million), a 12.1% increase from RMB93.9 million in the second quarter of 2012. |
| • | Net income attributable to ordinary shareholders in the second quarter of 2013 was RMB29.1 million ($4.7 million), a 21.9% decrease from RMB37.2 million in the second quarter of 2012. |
| • | Basic and diluted earnings per American depositary share (“ADS”)[2] in the second quarter of 2013 were both RMB0.65 ($0.11). |
| • | Adjusted EBITDA[3] (non-GAAP) in the second quarter of 2013 was RMB104.3 million ($17.0 million), a 11.3% increase from RMB93.7 million in the second quarter of 2012. |
Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, stated, “We are very pleased with our revenue, gross profit and adjusted EBITDA growth in the second quarter of 2013 as we continue to scale our network business and make further strides in our efforts to develop into a branded specialty cancer hospital company in China.”
“Revenue in our network business grew approximately 6.7% in the quarter with gross margin of 59.7%, both of which were notable improvements from our first quarter results. We added three new centers in the quarter, bringing our total count to 140 centers at the end of the second quarter. We are proud that we have consolidated our position as the largest operator of radiotherapy and diagnostic imaging centers in China.”
“In our Hospital segment, Chang’an Hospital delivered improved financial and operating results in the second quarter. As a hospital intended for the general population, Chang’an Hospital benefits from China’s enlarged social welfare network with strong patient flow. Our gross margin in this segment improved significantly since last quarter and we believe the performance will remain stabilized in the second half of 2013.”
“We continue to make meaningful progress in our telemedicine and web business units and expect these business units to start generating incremental medical revenue for our centers as well as achieve cost savings for our network business in the coming quarters.”
“As government policy in China increasingly favors the establishment of private healthcare institutions and higher demand for differentiated, high-quality healthcare services, we intend to focus on the construction and operation of CCM-branded specialty cancer hospitals in China. Our projects in Beijing and Guangzhou are both moving forward and remain on schedule. Our target is to complete the design of Concord Guangzhou Cancer Hospital in the second half of 2013 with construction expected to start in the first half of 2014.”
Dr. Yang concluded, “We believe our growth for the second half of 2013 will remain strong, as new centers in the network business entering productive stage and Chang’an Hospital carrying the strong momentum forward. We remain comfortable with our full year projection of 40%-47% revenue growth and adjusted EBITDA growth in the mid-teen levels for 2013.”
Second Quarter 2013 Results by Segment
Network business
The Company added three diagnostic centers in the second quarter of 2013, bringing the total number of centers in operation to 140 in 54 cities in China as of June 30, 2013. As of June 30,, the Company has agreements to establish eight additional centers, which are scheduled to open in the second half of the year.
Net revenue from the network business was RMB145.6 million ($23.7million) for the second quarter of 2013, representing an increase of 6.7% from the second quarter of 2012, primarily due to an increase in the number of patients in the Company’s existing centers as well as contribution from the new centers opened during the past 12 months.
Gross profit margin in the network business was 59.7% for the second quarter of 2013, compared to 68.7% for the second quarter of 2012 and 55.4% in the first quarter of 2013. The lower year-over-year gross profit margin was primarily due to increased compensation and operating cost at the Company’s centers. The improved quarter-over-quarter gross profit margin was mainly due to higher revenue and cost-saving measures implemented during the quarter.
Capital expenditure of the network business was RMB24.5 million ($4.0 million) for the second quarter of 2013, compared with RMB51.6 million in the second quarter of 2012.
Selling expenses in the network business were RMB25.6 million ($4.2 million) for the second quarter of 2013, representing an increase of 145.9% from the second quarter of 2012. The increase was mainly due to selling expenses relating to the Company’s telemedicine and web business, which amounted to RMB8.8 million ($1.4 million). The Company also incurred higher marketing and promotion expenses relating to existing centers.
General and administrative expenses in the network business were RMB24.3 million ($4.0 million), representing a decrease of 8.7% from the second quarter of 2012. The decrease was mainly due to lower professional fees incurred during the quarter. During the quarter, the Company spent RMB2.1 million ($0.3 million) in general and administrative expenses relating to the telemedicine and web business.
Accounts receivable from the network business was RMB209.3 million ($34.1 million) as of June 30, 2013, compared to RMB185.9 million as of March 31, 2013. The average period of sales outstanding for accounts receivable, or days sales outstanding (DSO), was 123 days for the second quarter of 2013, as compared to 155 days for the first quarter of 2013. The improved DSO was mainly due to strengthened collection efforts by the Company during the quarter.
As of June 30, 2013, the Company, not including Chang’an Hospital, had bank credit lines of RMB2,286 million ($372.5 million), of which RMB926.0 million ($150.9 million) was utilized.
During the second quarter of 2013, the Company handled 8,209 patient treatment cases and 84,943 patient diagnostic cases in the center network, representing a 6.9% decrease and a 60.8% increase from the second quarter of 2012, respectively.
Hospital business
Please note that financial results of Chang’an Hospital were consolidated into the Company’s operating results effective from the third quarter of 2012 when the Company consummated its acquisition of 52% equity interest in Chang’an Hospital.
Net revenue from the hospital business was RMB108.4 million ($17.7million) for the second quarter of 2013 compared to RMB92.3 million for the first quarter of 2013. Second quarter 2013 revenue from the hospital business consisted of:
| • | outpatient revenue of RMB25.8 million ($4.2 million), representing 24% of the net revenue from the hospital business; |
| • | inpatient revenue of RMB37.8 million ($6.2 million), representing 35% of the net revenue from the hospital business; and |
| • | medicine revenue of RMB44.8 million ($7.3 million), representing 41% of the net revenue from the hospital business. |
Cost of service for the hospital business for the second quarter of 2013 was RMB90.1 million ($14.7 million), of which the medicine cost was RMB38.5 million ($6.3 million) and the medical service cost was RMB51.6 million ($8.4 million).
Gross profit margin of the hospital business was 16.9% for the second quarter of 2013, a sequential improvement of 640 basis points from 10.5% in the first quarter of 2013. The improved gross margin was mainly due to increased contribution from the outpatient and inpatient business during the quarter.
Capital expenditure of the hospital business was RMB13.3 million ($2.2 million) for the second quarter of 2013, compared with RMB9.8 million in the first quarter of 2013.
General and administrative expenses in the hospital business were RMB6.2 million ($1.0 million), compared with RMB4.6 million in the first quarter of 2013.
As of June 30, 2013, Chang’an Hospital had accounts receivable of RMB38.1 million ($6.2 million), representing days sales outstanding of 29 days, as compared to 36 days for the first quarter of 2013.
Chang’an Hospital received 151,265 outpatients and 8,164 inpatients for the second quarter of 2013. The average bed utilization for the quarter was 93.4%. The average days of hospital stay was 10.2 days per patient for the quarter. Chang’an Hospital operated 1,015 beds as of June 30, 2013.
Chang’an Hospital is a leading private-owned, general service, for-profit hospital, located in Xi’an, Shanxi Province. Established in 2002, Chang’an Hospital had 57 departments with over 1,267 medical and non-medical staff as of June 30, 2013.
Share repurchase program
During the second quarter of 2013, the Company repurchased $0.05 million worth of stock, comprised of 12,524 ADSs, representing 37,572 ordinary shares.
Through June 30, 2013, the Company repurchased 2,306,332 ADSs, representing 6,918,996 ordinary shares, in the open market, for a total consideration of $8.12 million (including commissions) under the share repurchase program announced on October 9, 2012.
As of June 30, 2013, the Company had 18.9 million ADSs outstanding, representing 56.7 million ordinary shares.
2013 Outlook
Based on current market and operating conditions, estimated business expansion and forecasted Chang’an Hospital financial results, Concord Medical reiterates its full year 2013 guidance forecast of total estimated net revenue in the range of RMB930 million to RMB975 million, representing a 40% to 47% increase from 2012. Revenue from the Company’s network business and hospital business as a percent of total revenue are expected to be approximately 55% and 45% in 2013, respectively. Full year 2013 Adjusted EBITDA is expected to grow at the mid-teen level for the year compared to 2012.
Conference Call Information
Concord Medical’s management will hold an earnings conference call at 8:00 a.m. Eastern Daylight Time on August 13, 2013 (8:00 p.m. Beijing/Hong Kong time on August13, 2013).
Dial-in details for the earnings conference call are as follows:
U.S. Toll Free: 1-866-519-4004
U.K. Toll Free: 08082346646
International: 65 67239381
China Toll Free: 400-620-8038 / 800-819-0121
Hong Kong Toll Free: 800-930-346
Passcode: CCM
A replay of the conference call may be accessed by phone at the following numbers for 7 days:
U.S. Toll Free: 1-855-452-5696
International: +61 2 8199 0299
Conference ID: 26409831
Additionally, a live and archived webcast of this conference call will be available at http://ir.concordmedical.com/.
About Concord Medical
Concord Medical Services Holdings Limited operates the largest network of radiotherapy and diagnostic imaging centers in China, measured by revenues and the number of centers in operation and is the parent of Chang’an Hospital. As of June 30, 2013, the Company operated a network of 140 centers with 77 hospital partners that spanned 54 cities and 24 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com.
Safe Harbor Statement
This news release may contain “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging; and possible effects on consumers and hospitals, hospital construction, and suppliers, as a result of inflation and the Chinese government's policies and actions to control inflation. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The Company does not assume any obligation to update any forward-looking statement, except as required by law.
About Non-GAAP Financial Measures
To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense. The Company believes excluding share-based compensation expense from its GAAP financial measures is useful for its management and investors to assess and analyze the Company’s core operating results, as such expense is not directly attributable to the underlying performance of the Company’s business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expense are important in helping investors to understand the Company’s current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of Adjusted EBITDA, which is defined in this announcement as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses, and other adjustments. Other adjustments include foreign exchange gain (loss), gain (loss) from disposal of property, plant and equipment, and other expense or income. Furthermore, Adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.
For more information, please contact:
Concord Medical Services
Mr. Adam J. Sun (Chinese and English)
+86 10 5957 5266
adam.sun@concordmedical.com
Mr. Ting Jia (Chinese and English)
+86 10 5903 6688 (ext. 809)
ting.jia@concordmedical.com
Ms. Gloria Huang (Chinese and English)
+86 10 5903 6688 (ext. 639)
gloria.huang@concordmedical.com
ICR Inc.
In China:
Ms. Rene Jiang
+86 10 6583-7521
rene.jiang@icrinc.com
In the United States:
Mr. William Zima
+1 203-682-8233
William.Zima@icrinc.com
[1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.1374 to US$1.00, the effective noon buying rate as of June 30, 2013 in the City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York.
[2] Each ADS represents three ordinary shares of the Company.
[3] Definition of adjusted EBITDA: Adjusted EBITDA is defined as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange gain, gain(loss) from disposal of property, plant and equipment and other income or expense.
Concord Medical Services Holdings Co., Ltd.
Consolidated Balance Sheets
(in thousands)
| December 31, 2012 | June 30, 2013 | |||||||||||
| RMB | RMB (Unaudited) |
US$ (Unaudited) |
||||||||||
| ASSETS |
||||||||||||
| Current assets |
||||||||||||
| Cash |
75,382 | 215,034 | 35,037 | |||||||||
| Restricted cash, current portion |
284,047 | 279,105 | 45,476 | |||||||||
| Accounts receivable |
210,307 | 247,391 | 40,309 | |||||||||
| Inventories |
8,681 | 14,484 | 2,360 | |||||||||
| Prepayments and other current assets |
67,472 | 119,541 | 19,477 | |||||||||
| Net investments in direct financing leases, current portion |
89,451 | 119,255 | 19,431 | |||||||||
| Deferred tax assets, current portion |
16,593 | 23,927 | 3,899 | |||||||||
| Loan to a noncontrolling shareholder of a subsidiary |
100,000 | 93,410 | 15,220 | |||||||||
| Amount due from related parties |
1,200 | 1,973 | 321 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total current assets |
853,133 | 1,114,120 | 181,530 | |||||||||
|
|
|
|
|
|
|
|||||||
| Non-current assets |
||||||||||||
| Property, plant and equipment, net |
1,522,920 | 1,527,430 | 248,872 | |||||||||
| Goodwill |
292,885 | 292,885 | 47,721 | |||||||||
| Intangible assets, net |
146,512 | 132,117 | 21,527 | |||||||||
| Deposits for non-current assets |
162,938 | 70,962 | 11,562 | |||||||||
| Net investments in direct financing leases, non-current portion |
171,545 | 237,176 | 38,644 | |||||||||
| Deferred tax assets, non-current portion |
18,110 | 23,580 | 3,842 | |||||||||
| Equity method investments |
230,589 | 225,785 | 36,788 | |||||||||
| Other non-current assets |
114,758 | 126,730 | 20,649 | |||||||||
| Prepaid land lease payments |
90,124 | 88,858 | 14,478 | |||||||||
| Indemnification assets |
61,706 | 61,706 | 10,054 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total non-current assets |
2,812,087 | 2,787,229 | 454,137 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total assets |
3,665,220 | 3,901,349 | 635,667 | |||||||||
|
|
|
|
|
|
|
|||||||
| LIABILITIES AND EQUITY |
||||||||||||
| Current liabilities |
||||||||||||
| Short-term bank borrowings |
383,083 | 380,100 | 61,932 | |||||||||
| Long-term bank borrowings, current portion |
191,473 | 262,503 | 42,771 | |||||||||
| Accounts payable |
100,563 | 119,247 | 19,430 | |||||||||
| Accrual for purchase of property, plant and equipment |
40,691 | 35,833 | 5,838 | |||||||||
| Obligations under capital leases, current portion |
2,117 | 310 | 51 | |||||||||
| Accrued expenses and other liabilities |
92,040 | 101,221 | 16,492 | |||||||||
| Income tax payable |
22,433 | 30,956 | 5,044 | |||||||||
| Deferred revenue, current portion |
18,975 | 19,962 | 3,253 | |||||||||
| Amount due to related parties, current portion |
5,910 | 5,415 | 882 | |||||||||
| Deferred tax liabilities, current portion |
2,248 | 5,507 | 897 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total current liabilities |
859,533 | 961,054 | 156,590 | |||||||||
|
|
|
|
|
|
|
|||||||
| Non-current liabilities |
||||||||||||
| Long-term bank borrowings, non-current portion |
300,901 | 383,311 | 62,455 | |||||||||
| Accrued unrecognized tax benefits & surcharge, non-current portion |
67,719 | 67,719 | 11,034 | |||||||||
| Other long term liabilities |
34,646 | 32,402 | 5,278 | |||||||||
| Amount due to related parties, non-current |
26,828 | 26,828 | 4,371 | |||||||||
| Deferred tax liabilities, non-current portion |
35,683 | 38,309 | 6,242 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total non-current liabilities |
465,777 | 548,569 | 89,380 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total liabilities |
1,325,310 | 1,509,623 | 245,970 | |||||||||
|
|
|
|
|
|
|
|||||||
| Commitments and contingencies |
||||||||||||
| EQUITY |
||||||||||||
| Ordinary shares |
105 | 105 | 17 | |||||||||
| Treasuary stock |
(5 | ) | (4 | ) | (1 | ) | ||||||
| Additional paid-in capital |
2,517,496 | 2,518,952 | 410,427 | |||||||||
| Accumulated other comprehensive loss |
(16,955 | ) | (16,231 | ) | (2,645 | ) | ||||||
| Accumulated deficit |
(469,055 | ) | (420,291 | ) | (68,480 | ) | ||||||
|
|
|
|
|
|
|
|||||||
| Total Concord Medical Services Holdings Limited shareholders’ equity |
2,031,586 | 2,082,531 | 339,318 | |||||||||
| Noncontrolling interests |
308,324 | 309,195 | 50,379 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total equity |
2,339,910 | 2,391,726 | 389,697 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total liabilities and equity |
3,665,220 | 3,901,349 | 635,667 | |||||||||
|
|
|
|
|
|
|
|||||||
Concord Medical Services Holdings Limited
Consolidated Statements of Income
(in thousands, except per ADS data)
| For The Three Months Ended | ||||||||||||
| June 30, 2012 (*) | June 30, 2013 | |||||||||||
| RMB | RMB | US$ | ||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | ||||||||||
| Revenues, net of business tax, value-added tax and related surcharges |
||||||||||||
| Network |
136,530 | 145,610 | 23,725 | |||||||||
| Hospital-Medicine income |
— | 44,846 | 7,307 | |||||||||
| Hospital-Medical service income |
— | 63,590 | 10,361 | |||||||||
|
|
|
|
|
|
|
|||||||
| Total net revenues |
136,530 | 254,046 | 41,393 | |||||||||
| Cost of revenues |
||||||||||||
| Network |
(42,675 | ) | (58,750 | ) | (9,572 | ) | ||||||
| Hospital-Medicine cost |
— | (38,499 | ) | (6,273 | ) | |||||||
| Hospital-Medical service cost |
— | (51,630 | ) | (8,412 | ) | |||||||
|
|
|
|
|
|
|
|||||||
| Total cost of revenues |
(42,675 | ) | (148,879 | ) | (24,257 | ) | ||||||
| Gross profit |
93,855 | 105,167 | 17,136 | |||||||||
| Operating expenses |
||||||||||||
| Selling expenses |
(10,426 | ) | (25,633 | ) | (4,177 | ) | ||||||
| General and administrative expenses |
(26,580 | ) | (30,359 | ) | (4,947 | ) | ||||||
|
|
|
|
|
|
|
|||||||
| Operating income |
56,849 | 49,175 | 8,012 | |||||||||
| Interest expenses |
(3,504 | ) | (10,926 | ) | (1,780 | ) | ||||||
| Foreign exchange gain,net |
399 | 597 | 97 | |||||||||
| Gain (loss) on disposal of property, plant and equipment |
92 | (761 | ) | (124 | ) | |||||||
| Interest income |
1,367 | 4,340 | 707 | |||||||||
| Share of net profit of equity investees |
— | 4,978 | 811 | |||||||||
| Other income, net |
33 | 183 | 30 | |||||||||
|
|
|
|
|
|
|
|||||||
| Income before income taxes |
55,236 | 47,586 | 7,753 | |||||||||
| Income tax expenses |
(16,933 | ) | (15,089 | ) | (2,459 | ) | ||||||
| Net income |
38,303 | 32,497 | 5,294 | |||||||||
|
|
|
|
|
|
|
|||||||
| Net income attributable to noncontrolling interests |
1,087 | 3,417 | 557 | |||||||||
| Net income attributable to ordinary shareholders |
37,216 | 29,080 | 4,737 | |||||||||
|
|
|
|
|
|
|
|||||||
| Earnings per ADS |
||||||||||||
| Basic /Diluted |
0.80 | 0.65 | 0.11 | |||||||||
| Weighted average number of ADS outstanding: |
||||||||||||
| Basic /Diluted |
46,359,145 | 45,056,054 | 45,056,054 | |||||||||
| Other comprehensive income, net of tax |
||||||||||||
| Foreign currency translation |
184 | 474 | 77 | |||||||||
| Total other comprehensive income, net of tax |
184 | 474 | 77 | |||||||||
|
|
|
|
|
|
|
|||||||
| Comprehensive income |
38,487 | 32,971 | 5,371 | |||||||||
|
|
|
|
|
|
|
|||||||
| Comprehensive income attributable to noncontrolling interests |
1,087 | 3,417 | 557 | |||||||||
|
|
|
|
|
|
|
|||||||
| Comprehensive income attributable to Concord Medical Services Holdings Limited’s shareholders |
37,400 | 29,554 | 4,814 | |||||||||
|
|
|
|
|
|
|
|||||||
| (*) | Certain amounts in the prior year quarterly financial information are being reclassified for comparison purposes. |
Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures (*) (in RMB thousands, unaudited)
| For the three months ended June 30, 2012 |
For the three months ended June 30, 2013 |
|||||||||||||||||||||||
| GAAP Measure |
Adjustment | Non-GAAP Measure |
GAAP Measure |
Adjustment | Non-GAAP Measure |
|||||||||||||||||||
| Operating income |
56,849 | 2,282 | 59,131 | 49,175 | 2,231 | 51,406 | ||||||||||||||||||
| Net income |
38,303 | 2,282 | 40,585 | 32,497 | 2,231 | 34,728 | ||||||||||||||||||
| Basic earnings per ADS |
0.80 | 0.05 | 0.85 | 0.65 | 0.05 | 0.70 | ||||||||||||||||||
| Diluted earnings per ADS |
0.80 | 0.05 | 0.85 | 0.65 | 0.05 | 0.70 | ||||||||||||||||||
| (*) | The only adjustment is share-based compensation. |
Reconciliation from net income to adjusted EBITDA(*) (in RMB thousands, unaudited)
| For the three months ended June 30, 2012 |
For the three months ended June 30, 2013 |
|||||||
| Net income |
38,303 | 32,497 | ||||||
| Interest expenses, net |
2,137 | 6,586 | ||||||
| Income tax expenses |
16,933 | 15,089 | ||||||
| Depreciation and amortization |
34,568 | 47,918 | ||||||
| Share-based compensation |
2,282 | 2,231 | ||||||
| Other adjustments |
(524 | ) | (19 | ) | ||||
|
|
|
|
|
|||||
| Adjusted EBITDA |
93,699 | 104,302 | ||||||
|
|
|
|
|
|||||
| (*) | Definition of adjusted EBITDA: Adjusted EBITDA is defined as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange gain, gain (loss) from disposal of property, plant and equipment and other income or expense. |